LivingGLP1
Study S000716

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Included trial: extracted dataClinicalTrials.gov recordStudy Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration
NCT03574597
Acronym
SELECT
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
17604
Start
2018-10-24
Primary completion
2023-06-21
Lead sponsor
Novo Nordisk A/S
Conditions
Overweight; Obesity
Interventions
DRUG:Semaglutide; DRUG:Placebo (semaglutide)
Results posted
TRUE
Individual participant data sharing
YES
Secondary identifiers
REGISTRY:2017-003380-35; OTHER:U1111-1200-5564; NIH:2017

Registered primary outcomes

  • Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke [From randomisation (week 0) up to 240 weeks]

Linked records (29)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0001404Predicting GLP-1 Discontinuation From Pharmacy Claims.
Sisodia A, The American journal of managed care
2026Nonrandomized studyPMID 42663544DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:42663544
R0002643Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.
Ostrominski JW, JAMA cardiology
2026Randomized trialPMID 42747817DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:42747817
R0003863Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.
Plutzky J, Circulation
2026Randomized trialPMID 42610271DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:42610271
R0009863Calculating cost per event avoided using a composite number needed to treat.
Toliver J, Journal of medical economics
2026OtherPMID 41562647DOIcites ClinicalTrials.gov:NCT03574597
R0014931Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Meyhöfer SM, Nature medicine
2026Randomized trialPMID 41928037DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:41928037
R0014951Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.
Nicholls SJ, JAMA cardiology
2026Randomized trialPMID 41433034DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:41433034
R0018814Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.
Borlaug BA, JACC. Heart failure
2026OtherPMID 41099689DOIcites ClinicalTrials.gov:NCT03574597
R0053978Semaglutide Impacts Proteomic Signatures Related to Dementia Risk in the SELECT Cardiovascular Outcomes Trial (P6-12.007)
Paul Mystkowski, Neurology
2026Other trialDOIcites ClinicalTrials.gov:NCT03574597
R0002391The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Mendonça L, Clinical journal of the American Society of Nephrology : CJASN
2025Systematic reviewPMID 39480988DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:39480988
R0010240Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.
Badve SV, The lancet. Diabetes & endocrinology
2025Systematic reviewPMID 39608381DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:39608381
R0016846Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
Deanfield J, Lancet (London, England)
2025Randomized trialPMID 41138739DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:41138739
R0018247Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.
McEwan P, Journal of medical economics
2025Nonrandomized studyPMID 39882599DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:39882599
R0018311The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
Lübker C, Advances in therapy
2025Randomized trialPMID 40156748DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:40156748
R0015980Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Deanfield J, Lancet (London, England)
2024Randomized trialPMID 39181597DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:39181597
R0018379The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
Scirica BM, Journal of the American College of Cardiology
2024Randomized trialPMID 39217559DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:39217559
R0018713Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Ryan DH, Nature medicine
2024Other trialPMID 38740993DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:38740993
R0019192Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
Kosiborod MN, Lancet (London, England)
2024Randomized trialPMID 39222642DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:39222642
R0019766Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Colhoun HM, Nature medicine
2024Other trialPMID 38796653DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:38796653
R0042508Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
J Deanfield (7667639), Aston Publications Explorer (Aston University)
2024Randomized trialcites ClinicalTrials.gov:NCT03574597
R0007476Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.
Michos ED, American journal of preventive cardiology
2023Other trialPMID 37313358DOIcites ClinicalTrials.gov:NCT03574597
R0008068Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, The New England journal of medicine
2023Randomized trialPMID 37952131DOIcites ClinicalTrials.gov:NCT03574597; registry reference RESULT:37952131
R0049754Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease
Ian A.C. Rowe, Hepatology
2023Nonrandomized studyPMID 36738088DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:36738088
R0050208Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide
Nikolaus Marx, European Heart Journal
2023Randomized trialDOIcites ClinicalTrials.gov:NCT03574597
R0052122Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)
John Eric Deanfield, European Heart Journal
2023Randomized trialDOIcites ClinicalTrials.gov:NCT03574597
R0005859Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.
Leite AR, Diabetes, obesity & metabolism
2022Systematic reviewPMID 35373878DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:35373878
R0022889Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.
Mares AC, Current opinion in cardiology
2022Narrative reviewPMID 35175229DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:35175229
R0011646Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
Kanie T, The Cochrane database of systematic reviews
2021Systematic reviewPMID 34693515DOIcites ClinicalTrials.gov:NCT03574597; registry reference DERIVED:34693515
R0023399Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, The New England journal of medicine
2021Randomized trialPMID 33567185DOIregistry reference RESULT:33567185
R0016197Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
Ryan DH, American heart journal
2020ProtocolPMID 32916609DOIregistry reference RESULT:32916609